SYMBICORT® in the Treatment of COPD - Full Text View

SYMBICORT® in the Treatment of COPD (SRP COPD)

This study has been completed.

First Received on November 26, 2007. Last Updated on January 27, 2011 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00564499

Purpose

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Condition
COPD

Study Type:	Observational
Study Design:	Observational Model: Case-Crossover Time Perspective: Prospective
Official Title:	A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners

Resource links provided by NLM:

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Study Start Date:	March 2006
Study Completion Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients

Criteria

Inclusion Criteria:

patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

patients who recently quit smoking (<3months)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00564499

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

E Louis, PR

Université Libre de Liège

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00564499 History of Changes
Other Study ID Numbers:	SRP-RB-COPD-2005/1
Study First Received:	November 26, 2007
Last Updated:	January 27, 2011
Health Authority:	Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:

COPD
Symbicort
General Practitioners

Additional relevant MeSH terms:

Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases
Symbicort

Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 09, 2012